Defeat Duchenne Canada is proud to announce a research partnership and infrastructure grant to support the development of Satellos’ novel approach to treating Duchenne.
Satellos scientists are developing small molecule drugs that they believe will restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The company’s drug candidates regulate the activity of an enzyme, codenamed PTP-X, which Satellos discovered is involved in controlling muscle stem cell function, allowing these stem cells to properly divide and repair damaged tissue that accumulates in the muscles of Duchenne patients.
“This grant to purchase critical equipment will enable us to enhance our research throughput, thereby accelerating our evaluation and development of new drug candidates. Despite an incredibly tough COVID environment, Defeat Duchenne Canada has put together its largest pool of research funding in its 26-year history, and we could not be more proud to have obtained their support in advancing our unique approach to treating Duchenne.”Frank Gleeson, CEO of Satellos Bioscience Inc.
“We are very pleased to announce our partnership with Satellos and to directly support the development of their exciting science. Defeat Duchenne Canada understands that research is the only way to defeat Duchenne, and we believe that evaluating and testing groundbreaking approaches to drug development, like that of Satellos, will ultimately lead to better outcomes for patients and their families.”Perry Esler, Executive Director of Defeat Duchenne Canada
Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity – a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos’ lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenXTM, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc. Founded in 2018, Satellos is headquartered in Canada.
Click on the button below to read the full press release.